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Interstitial pneumonitis after rituximab theraphy for non 
hodgikin’s lymphoma: the radiological findings
Kim, Ji Yeon; Do, Kyung-Hyun; Lee, Jin Seong 
Research Institute of Radiology, Department of Radiology, Asan Medi-
cal Center, University of Ulsan College of Medicine, Seoul, Korea
Background: Rituximab, anti-CD20 IgG1 monoclonal antibody, is an 
important chemotherapeutic agent for non Hodgikin lymphoma. This 
drug is generally tolerated, but it can be associated with various adverse 
effects, including coughing, rhinitis, bronchospasm or dyspnea. Also 
this drug has rarely been late pulmonary complication, such as intersti-
tial pneumonia and fatal alveolar hemorrhage. 
CT ﬁndings of the rituximab induced interstitial lung disease have not 
been documented to our knowledge. We suggested the radiological 
ﬁnding of the rituximab induced interstitial lung disease on chest CT 
and positron emission tomography.
Materials and Methods: We reviewed nineteen patients, who had 
received rituximab for non-Hodgikin B cell lymphoma and complained 
respiratory symptoms after treated with rituximab, between March 
2003 and November 2004. Finally three patients (one men and two 
women; age range, 46-67 years; mean age, 58 years) noticed episodic 
symptom of dry cough, dyspnea or DOE after each rituximab infusion 
for no particular reason. They performed chest CT using 16 channel 
multi-detector CT and positron emission tomography using F-18 ﬂuo-
rodeoxyglucose. As two patients underwent bronchoscopic biopsy, one 
patient was showed with diffuse alveolar damage and focal bronchiol-
itis obliterance with organizing pneumonia component and the other 
patient was showed chronic interstitial inﬂammation.
Results: CT scan revealed patchy ground glass opacities and interlobu-
lar septal thickening throughout the bilateral lung parenchyma with 
posterior predominancy. 
In two patients, proton emission tomograph demonstrated diffuse hy-
permetabolic lesions with predominantly dependent portion (max SUV 
1.0 - 2.2) in the bilateral lung parenchyma, correlated with CT ﬁnding. 
There was no hypermetabolic lesion in the one patient, and his CT ﬁnd-
ings were subtlest in the three patients.
Previous two patients were followed chest CT scan with steroid ther-
apy, diffuse ground glass opacities were disappeared. Dyspnea of the 
other patient with subtlest CT ﬁndings was improved after rituximab 
was stopped.
Conclusion: In any patients with a history of rituximab therapy who 
complain new or progressive respiratory symptoms, if the diffuse 
ground glass attenuation was noted on HRCT and diffuse mild hyper-
metabolic lesions in the bilateral lung parenchyma on PET, pulmonary 
toxicity of the rituximab theraphy should be considered.
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The influence of positron emission tomography (FDG-PET/CT) on 
management of patients with non small cell lung cancer (NSCLC)
Kim, Su Woon1 Appel, Wiebke1 Hill, Jonathan1 Coffey, John1 Kane, 
Thomas2 
1 Lancashire Teaching Hospitals NHS Trust, Preston, UK 2 Blackpool 
Victoria Hospital, Blackpool, UK 
Aims: To assess the inﬂuence of PET/CT scan compared to Com-
puted Tomography (CT) in management of non small cell lung cancer 
(NSCLC). 
Background: Access to PET/CT scanning has been very variable in 
the United Kingdom. Following guidance by the National Institute of 
Clinical Excellence (NICE) in Feb 2005 there was some interest from 
the local Primary Care Trusts (PCT) to investigate whether investment 
into a PET/CT scanner was valuable to patients in the cancer network.
Patients and methods: 107 patients at one cancer centre underwent 
PET/CT scanning for suspected lung cancer between September 2005 
and March 2006. PET/CT results were compared with the ﬁndings of 
CT scans on the same patients. Subsequent assessment revealed benign 
pathology in 37 patients and NSCLC in 70 patients. A retrospective 
analysis of these 70 patients was performed. The following questions 
were asked: demographic details, histology, TNM stage (both CT and 
PET/CT), Date of scans, management decision based on CT and PET/
CT, any changes in management decision.
Results: When comparing CT scan stage with stage of PET/CT scan, 
30/70 cases (43%) were upstaged and 11 cases (16%) were downstaged 
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by PET/CT scan. No difference in staging was seen in 26 cases (37%). 
3 cases (4%) could not be assessed because of incomplete records. 
In 19 out of 67 cases (28%) PET/CT scan changed the management 
decision from radical to palliative treatment and in 11 cases (17%) 
the management changed from palliative to radical treatment. Overall 
the difference in staging led to a change in management in 30 patients 
(45%). Congruent results were seen in 37 cases (55%).
Conclusion: This was a small retrospective study. However, it 
conﬁrmed that PET/CT is invaluable for the correct management of 
NSCLC patients. This ﬁgure is consistent with current literature where 
40-45% of changes in management are quoted. 
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Role of PET in evaluation of lung cancer
Komurcuoglu, Berna E.1 Gayaf, Mine1 Korkmaz, Esra1 Özden, Emel1 
Kumanlığolu, Kamil2 
1 Izmir Training And Research Hospital For Chest Disease, Izmir, Tur-
key 2 Ege university, Izmir, Turkey 
PET is a widely used diagnostic method of nuclear radiology in the 
diagnosis and evaluation of malignancies. Apart from other malignan-
cies PETespecially has an important role in diagnosis, staging and 
therapy of lung cancer in our daily practice. In this study we evaluated 
retrospectively our patients whom PET was used during their therapies. 
Prediagnosis of the patients, the role of PET in disease staging, and the 
role of PET in therapy changes were analised. 34 patients were evalu-
ated, consisting 30 male, 4 female. The patients median age was 55. 
PET, was performed to ﬁnd the primery site of metastasis in 11 cases, 
primary tumor relaps after lung cancer surgery in 4 cases, preoperative 
assesement in 14 cases and for staging after neuadjuvant therapy in 5 
cases. PET staging made the clinic stage up in 13 of 23 lung cancer 
patients and down in 4 patient. In 6 patients PET didn’t change the 
clinic stage. 
Conclusion: PET should be thought in stagingthe lung cancer patients 
especially who will be planned to treat with invazive therapy modalities
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Lung cancer cases detected by repeated low-dose CT screening
Kondo, Tetsuro Mori, Kiyoshi Kodama, Tetsuro 
Dept. of Thoracic Disease, Tochigi Cancer Center, Utsunomiya, Japan
Purpose: To review lung cancer cases detected by repeated low-dose 
CT screening, and then to clarify pitfalls in interpretation and observa-
tion of repeated screenee.
Methods: From May 2000 to March 2005, asymptomatic 4,176 sub-
jects (2,490 male and 1,686 female) underwent low-dose CT screening. 
A total 13 subjects were found to have lung cancer over a period of 5 
years. Among them, 3 cases were repeated screenee case. These 3 cases 
were reviewed gender, age, smoking pack years, tumor size, histologi-
cal subtype, disease stage and repeated CT images.
Results: Case one was 61 years old female with well differentiated ad-
enocarcinoma of stage IA disease. She underwent 3 times of CT screen-
ing until diagnosed lung cancer. First time her lesion was estimated 
post inﬂammatory scar, but it was gradually grown in size. Second case 
was 66 years old male with small cell carcinoma of stage IIA disease. 
He underwent 4 times of CT screening until diagnosed lung cancer. 
Until second repeated CT screening, his thoracic CT images were no 
evidence of disease. In 3rd CT screening, he was detected small nodule 
in peripheral lung, but it was disappeared. In 4th CT screening, left 
hilar lymphadenopathy was detected. Trans-bronchial biopsy specimen 
proved small cell carcinoma. Third case was 58 years old male with 
squamous cell carcinoma of stage IIIA disease. He underwent 2 times 
of CT screening until diagnosed lung cancer. He was detected a nodule 
in ﬁrst CT screening, but it was estimated decreased in size. In second 
CT screening, this nodule was grown in size again. First case of female 
was never-smoker, but second and third cases were 92 and 38 pack-
years smoker, respectively.
Conclusions: Many of the lung cancers detected by low-dose CT 
screening were early stage disease. On the other hand, there is rapid 
growth case in a short period, we must remember these case can be 
detected by faint change in a comparative interpretation and a strict 
observation. Especially, nodules detected in heavy-smoking screenee 
must be paid attention to the faint change.
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Combined endoscopic transbronchial and transesophageal 
ultrasound-guided biopsy of centrally located lung tumours 
following a nondiagnostic bronchoscopy
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Objective: The aim of the present study was to test the use of EBUS 
TBNA and EUS FNA in patients with an undiagnosed solid lesion of 
unknown origin in the lung or mediastinum
Methods: 
EBUS TBNA and EUS FNA was performed before mediastinoscopy.
52 patients prospective referred - 5 patients with a tumour in the medi-
astinum 47 patients with an undiagnosed tumour in the lung.
Bronchoscopy and TBNA had been performed in all patients without 
obtaining a diagnose.
103 lymph nodes and 5 tumours were biopsied
All the diagnosis was confrmed either by mediastinoscopy, thoracoto-
my/ thoracoscopy
Results: 
103 lymph nodes and 5 tumours were biopsied
EBUS TBNA positive for cancer in 34 lymph nodes
EUS FNA positive for cancer in 37 lymph nodes 
EUS and EBUS positive for cancer in 2 tumours
EUS and EBUS showed speciﬁc benign changes i 3 tumours
In one patient both EUS FNA and EBUS TBNA shoved benign changes 
and a cancer was found in a N1 lymph nodes during operation
3 biopsies were inconclusive and 32 lymph nodes biopsies showed cor-
rectly normal lymph cells 
The diagnostic yield was 97% (105/108) 
31 patients were diagnosed with a malignant diagnosis and 3 patients 
with a speciﬁc benign diagnosis
